| Variables . | Values . |
|---|---|
| Diagnosis, n | 6 PM, 9 NM, 24 DM, 11 anti-synthetase syndrome (without myositis; 8 myositis patients with AS antibody) |
| Age at enrolment, years, mean (s.d.) | 51.6 (14.9) |
| Disease duration, years, mean (s.d.) | 3.0 (4.2) |
| Gender, female/male, n | 30/20 |
| Ethnicity, Caucasian/African American/Asian, n | 47/2/1 |
| Autoantibodies, n/N (%) | 38/50 (76) |
| MSA, n/N (%) | 33/50 (66) |
| Jo-1 | 11 |
| SRP | 5 |
| TIF-1γ | 4 |
| Mi-2 | 4 |
| Pl-12 | 3 |
| Pl-7 | 1 |
| EJ | 2 |
| OJ | 1 |
| MDA5 | 1 |
| SAE | 1 |
| MAA, n/N (%) | 5/50 (10%) |
| RO52 | 3 |
| RO60 | 2 |
| Groups, n (%) | |
| Active muscle disease | 32 (64) |
| Active ILD | 12 (24) |
| Active skin disease | 11 (22) |
| Myositis outcome measures, mean (s.d.) | |
| Physician global disease activity | 3.5 (2.4) |
| MMT-9 (maximum score of 80) | 73.9 ( 8.7) |
| Extramuscular disease activity | 2.1 (1.9) |
| Creatine kinase (U/L) | 1152 (12 396) |
| HAQ-DI | 0.8 (0.8) |
| Patient global disease activity | 4.2 (2.8) |
| Muscle disease activity | 2.2 (2.4) |
| Myositis global damage score | 0.7 (1.1) |
| Pulmonary disease activity | 0.8 (1.7) |
| Cutaneous disease activity | 0.7 (1.3) |
| Variables . | Values . |
|---|---|
| Diagnosis, n | 6 PM, 9 NM, 24 DM, 11 anti-synthetase syndrome (without myositis; 8 myositis patients with AS antibody) |
| Age at enrolment, years, mean (s.d.) | 51.6 (14.9) |
| Disease duration, years, mean (s.d.) | 3.0 (4.2) |
| Gender, female/male, n | 30/20 |
| Ethnicity, Caucasian/African American/Asian, n | 47/2/1 |
| Autoantibodies, n/N (%) | 38/50 (76) |
| MSA, n/N (%) | 33/50 (66) |
| Jo-1 | 11 |
| SRP | 5 |
| TIF-1γ | 4 |
| Mi-2 | 4 |
| Pl-12 | 3 |
| Pl-7 | 1 |
| EJ | 2 |
| OJ | 1 |
| MDA5 | 1 |
| SAE | 1 |
| MAA, n/N (%) | 5/50 (10%) |
| RO52 | 3 |
| RO60 | 2 |
| Groups, n (%) | |
| Active muscle disease | 32 (64) |
| Active ILD | 12 (24) |
| Active skin disease | 11 (22) |
| Myositis outcome measures, mean (s.d.) | |
| Physician global disease activity | 3.5 (2.4) |
| MMT-9 (maximum score of 80) | 73.9 ( 8.7) |
| Extramuscular disease activity | 2.1 (1.9) |
| Creatine kinase (U/L) | 1152 (12 396) |
| HAQ-DI | 0.8 (0.8) |
| Patient global disease activity | 4.2 (2.8) |
| Muscle disease activity | 2.2 (2.4) |
| Myositis global damage score | 0.7 (1.1) |
| Pulmonary disease activity | 0.8 (1.7) |
| Cutaneous disease activity | 0.7 (1.3) |
All global activity and damage scores are rated on a 10 cm visual analogue scale of the MDAT and myositis damage index (MDI); MAA: myositis-associated antibodies; MSA: myositis-specific antibodies.
| Variables . | Values . |
|---|---|
| Diagnosis, n | 6 PM, 9 NM, 24 DM, 11 anti-synthetase syndrome (without myositis; 8 myositis patients with AS antibody) |
| Age at enrolment, years, mean (s.d.) | 51.6 (14.9) |
| Disease duration, years, mean (s.d.) | 3.0 (4.2) |
| Gender, female/male, n | 30/20 |
| Ethnicity, Caucasian/African American/Asian, n | 47/2/1 |
| Autoantibodies, n/N (%) | 38/50 (76) |
| MSA, n/N (%) | 33/50 (66) |
| Jo-1 | 11 |
| SRP | 5 |
| TIF-1γ | 4 |
| Mi-2 | 4 |
| Pl-12 | 3 |
| Pl-7 | 1 |
| EJ | 2 |
| OJ | 1 |
| MDA5 | 1 |
| SAE | 1 |
| MAA, n/N (%) | 5/50 (10%) |
| RO52 | 3 |
| RO60 | 2 |
| Groups, n (%) | |
| Active muscle disease | 32 (64) |
| Active ILD | 12 (24) |
| Active skin disease | 11 (22) |
| Myositis outcome measures, mean (s.d.) | |
| Physician global disease activity | 3.5 (2.4) |
| MMT-9 (maximum score of 80) | 73.9 ( 8.7) |
| Extramuscular disease activity | 2.1 (1.9) |
| Creatine kinase (U/L) | 1152 (12 396) |
| HAQ-DI | 0.8 (0.8) |
| Patient global disease activity | 4.2 (2.8) |
| Muscle disease activity | 2.2 (2.4) |
| Myositis global damage score | 0.7 (1.1) |
| Pulmonary disease activity | 0.8 (1.7) |
| Cutaneous disease activity | 0.7 (1.3) |
| Variables . | Values . |
|---|---|
| Diagnosis, n | 6 PM, 9 NM, 24 DM, 11 anti-synthetase syndrome (without myositis; 8 myositis patients with AS antibody) |
| Age at enrolment, years, mean (s.d.) | 51.6 (14.9) |
| Disease duration, years, mean (s.d.) | 3.0 (4.2) |
| Gender, female/male, n | 30/20 |
| Ethnicity, Caucasian/African American/Asian, n | 47/2/1 |
| Autoantibodies, n/N (%) | 38/50 (76) |
| MSA, n/N (%) | 33/50 (66) |
| Jo-1 | 11 |
| SRP | 5 |
| TIF-1γ | 4 |
| Mi-2 | 4 |
| Pl-12 | 3 |
| Pl-7 | 1 |
| EJ | 2 |
| OJ | 1 |
| MDA5 | 1 |
| SAE | 1 |
| MAA, n/N (%) | 5/50 (10%) |
| RO52 | 3 |
| RO60 | 2 |
| Groups, n (%) | |
| Active muscle disease | 32 (64) |
| Active ILD | 12 (24) |
| Active skin disease | 11 (22) |
| Myositis outcome measures, mean (s.d.) | |
| Physician global disease activity | 3.5 (2.4) |
| MMT-9 (maximum score of 80) | 73.9 ( 8.7) |
| Extramuscular disease activity | 2.1 (1.9) |
| Creatine kinase (U/L) | 1152 (12 396) |
| HAQ-DI | 0.8 (0.8) |
| Patient global disease activity | 4.2 (2.8) |
| Muscle disease activity | 2.2 (2.4) |
| Myositis global damage score | 0.7 (1.1) |
| Pulmonary disease activity | 0.8 (1.7) |
| Cutaneous disease activity | 0.7 (1.3) |
All global activity and damage scores are rated on a 10 cm visual analogue scale of the MDAT and myositis damage index (MDI); MAA: myositis-associated antibodies; MSA: myositis-specific antibodies.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
